-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Initiates Coverage On Trevi Therapeutics with Overweight Rating, Announces Price Target of $18

Benzinga·08/21/2025 11:16:06
Listen to the news
Morgan Stanley analyst Judah Frommer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and announces Price Target of $18.